JP4942297B2 - 肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用 - Google Patents

肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用 Download PDF

Info

Publication number
JP4942297B2
JP4942297B2 JP2004546290A JP2004546290A JP4942297B2 JP 4942297 B2 JP4942297 B2 JP 4942297B2 JP 2004546290 A JP2004546290 A JP 2004546290A JP 2004546290 A JP2004546290 A JP 2004546290A JP 4942297 B2 JP4942297 B2 JP 4942297B2
Authority
JP
Japan
Prior art keywords
pulmonary hypertension
methyl
compound
pulmonary
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004546290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006505582A5 (https=
JP2006505582A (ja
Inventor
ジョゼフ・アレキサンダー・ラスキー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Publication of JP2006505582A publication Critical patent/JP2006505582A/ja
Publication of JP2006505582A5 publication Critical patent/JP2006505582A5/ja
Application granted granted Critical
Publication of JP4942297B2 publication Critical patent/JP4942297B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004546290A 2002-10-25 2003-10-20 肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用 Expired - Fee Related JP4942297B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42131802P 2002-10-25 2002-10-25
US60/421,318 2002-10-25
PCT/IB2003/004671 WO2004037261A1 (en) 2002-10-25 2003-10-20 Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension

Publications (3)

Publication Number Publication Date
JP2006505582A JP2006505582A (ja) 2006-02-16
JP2006505582A5 JP2006505582A5 (https=) 2006-12-07
JP4942297B2 true JP4942297B2 (ja) 2012-05-30

Family

ID=32176700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004546290A Expired - Fee Related JP4942297B2 (ja) 2002-10-25 2003-10-20 肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用

Country Status (4)

Country Link
US (3) US20060154936A1 (https=)
JP (1) JP4942297B2 (https=)
AU (1) AU2003272007A1 (https=)
WO (1) WO2004037261A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1392313E (pt) * 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
AU2003244922A1 (en) * 2002-06-28 2004-01-19 The Administrators Of The Tulane Educational Fund 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
ES2373912T3 (es) * 2005-01-28 2012-02-10 Novartis Ag Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulación de la actividad de quinasa tie-2.
EP1741432A1 (de) * 2005-07-07 2007-01-10 Universitätsklinikum Freiburg Tyrosinkinase-Inhibitor Imatinib zur Behandlung von Bluthochdruck
RU2431484C2 (ru) * 2005-11-10 2011-10-20 Байер Шеринг Фарма Акциенгезельшафт Диарилмочевина для лечения легочной гипертензии
CN101784269A (zh) * 2007-06-26 2010-07-21 莱西肯医药有限公司 治疗由5-羟色胺介导的疾病和病症的方法
CN101815534A (zh) * 2007-07-11 2010-08-25 莱西肯医药有限公司 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物
BRPI0917491A2 (pt) * 2008-08-13 2015-12-01 Novartis Ag tratamento de hipertensao arterial pulmonar
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
KR20190005708A (ko) * 2017-07-05 2019-01-16 이화여자대학교 산학협력단 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527523A (ja) * 2002-03-15 2005-09-15 ノバルティス　アクチエンゲゼルシャフト ＡｎｇＩＩ介在性疾病を処置するための４−（４−メチルピペラジン−１−イルメチル）−Ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イル−アミノ］フェニル］−ベンズアミド

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
AU2002220720B2 (en) * 2000-11-28 2006-09-14 Mondobiotech Ag Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527523A (ja) * 2002-03-15 2005-09-15 ノバルティス　アクチエンゲゼルシャフト ＡｎｇＩＩ介在性疾病を処置するための４−（４−メチルピペラジン−１−イルメチル）−Ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イル−アミノ］フェニル］−ベンズアミド

Also Published As

Publication number Publication date
AU2003272007A1 (en) 2004-05-13
US20060154936A1 (en) 2006-07-13
WO2004037261A1 (en) 2004-05-06
JP2006505582A (ja) 2006-02-16
US20110046150A1 (en) 2011-02-24
US20120214819A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
US20110046150A1 (en) Use of n--4-(3-pyridyl)-2-pyridine-amine for the treatment of pulmonary hypertension
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
JP2008515905A5 (https=)
TW202339743A (zh) 治療貧血之組合物及方法
JP2011522876A (ja) 永続性心房細動を予防するためのドロネダロン
EA026074B1 (ru) Способы, включающие применение композиции амбризентана и тадалафила для лечения легочной артериальной гипертензии
JP4714139B2 (ja) 心臓保護的デルタオピオイド受容体アゴニストおよびその使用法
JP2010514696A (ja) 心血管症状の低減
PT1259242E (pt) Utilização de inibidores de tirosina quinase de receptores de pdgf para o tratamento da nefropatia diabética
JPH0422889B2 (https=)
JP2017014224A (ja) 帯状疱疹関連痛の急性期疼痛の予防又は治療剤
TW201026684A (en) Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy
JP2013107893A (ja) 神経線維腫症の処置のためのピリミジルアミノベンズアミド誘導体
TW200817000A (en) New paediatric indications for direct thrombin inhibitors
JP2007505939A (ja) Ｖｅｇｆ受容体阻害剤と他の治療剤の組み合わせ
JP4609877B2 (ja) 慢性拒絶反応抑制剤
JP2007537184A (ja) 抗血小板剤に対する耐性を治療するためのジピリダモールの使用
JP6539206B2 (ja) 肺高血圧症の治療のためのベータ−３アドレナリン受容体アゴニストの使用
CA3040815C (en) Anti-proliferative agents for treating pah
CN112672742B (zh) 纤维化治疗用医药组合物
US20050277664A1 (en) Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid generation
KR20060130619A (ko) 유기 화합물의 조합물
JP5437331B2 (ja) 心臓機能を改善するための医薬組成物及びその方法
JP2003528050A (ja) 愛玩動物におけるピリミジン系のエンドセリンアンタゴニストの使用
JP2002338467A (ja) アデニル酸シクラーゼ５型阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101020

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111107

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20111107

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20111109

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120228

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120228

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150309

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees